Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | MIF | P14174 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31236317 | 0.84 | MAPK1 (0.66) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL3027838 | 0.84 | MAPK1 (0.66) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL536696 | 0.81 | MAPK1 (0.62) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL17039271 | 0.81 | MAPK1 (0.62) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL9364339 | 0.81 | MAPK1 (0.62) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL10915913 | 0.78 | MAPK1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL5537126 | 0.78 | MAPK1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL904819 | 0.78 | MAPK1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL3049673 | 0.78 | MAPK1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL12124412 | 0.78 | MAPK1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054448-A1 | Amino Acid Derivatives as Histone Deacetylase (HDAC) Inhibitors | JONES PHILIP | 2009-02-26 | — | — | US | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054448-A1 | Amino Acid Derivatives as Histone Deacetylase (HDAC) Inhibitors | HDAC5, HDAC1, HDAC11 | MAPK1 1181/4885TSHR 1377/4885HPGD 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.